We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Vols saber com serà la teva estada a l’Hospital Universitari Vall d’Hebron? Aquí trobaràs tota la informació.
Dr. Carlos Jiménez Jiménez, Childhood Cancer and Blood Disorders group.
Epigenetic programming during development is essential for the determination of cell lineages, and its alteration contributes to the initiation of embryonal tumors. In neuroblastoma, neural crest progenitors block their natural differentiation course into sympathoadrenergic cells, leading to an aggressive and metastatic pediatric cancer. The study of the epigenetic regulators responsible for oncogenic epigenomic networks is crucial to develop new epigenetic-based therapies against these tumors.
mSWI/SNF ATP-dependent chromatin remodeling complexes act genome-wide translating epigenetic signals into opened chromatin states. With the aim of understanding the role of mSWI/SNF complexes in the control of the oncogenic epigenomes of neuroblastoma, we carried out a functional characterization of these remodelers in neuroblastoma cells by proteomic, transcriptomic and chromatin accessibility approaches, discovering that only the structural disruption of BAF subtype complexes impairs proliferation by promoting cell cycle blockade. Genome-wide chromatin remodeling analysis coupled with whole transcriptome data revealed that BAF disruption results in the epigenetic repression of an extensive invasiveness-related expression program, involving integrins, cadherins and key mesenchymal regulators, thereby reducing extracellular matrix adhesion and invasion in vitro, together with a drastic inhibition of neuroblastoma metastasis initiation and growth in vivo.
We defined a novel ATPase-independent role for BAF complex in the maintenance of an epigenomic program that allows neuroblastoma invasiveness and metastasis, urging the development of new BAF pharmacological structural disruptors for its therapeutic exploitation in metastatic neuroblastoma.
Host: Dr. Miguel Segura, Childhood Cancer and Blood Disorders group.
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.